AbbVie Price to Sales Ratio 2010-2018 | ABBV

Historical PS ratio values for AbbVie (ABBV) over the last 10 years. The current P/S ratio for AbbVie as of March 22, 2019 is .
AbbVie P/S Ratio Historical Data
Date Stock Price TTM Sales per Share Price to Sales Ratio
2019-03-22 79.76 3.79
2018-12-31 91.04 $21.05 4.33
2018-09-30 92.42 $20.50 4.51
2018-06-30 89.64 $19.43 4.61
2018-03-31 90.63 $18.50 4.90
2017-12-31 91.94 $17.61 5.22
2017-09-30 83.89 $16.95 4.95
2017-06-30 67.85 $16.51 4.11
2017-03-31 60.37 $16.12 3.74
2016-12-31 57.42 $15.71 3.66
2016-09-30 57.30 $15.45 3.71
2016-06-30 55.75 $15.10 3.69
2016-03-31 50.95 $14.50 3.51
2015-12-31 52.26 $13.97 3.74
2015-09-30 47.54 $13.45 3.54
2015-06-30 58.28 $12.99 4.49
2015-03-31 50.36 $12.70 3.97
2014-12-31 55.87 $12.40 4.50
2014-09-30 48.94 $12.20 4.01
2014-06-30 47.45 $11.99 3.96
2014-03-31 42.83 $11.84 3.62
2013-12-31 43.65 $11.70 3.73
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $117.653B $32.753B
AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie aims to help patients' live healthier lives and collaborate on sustainable healthcare solutions.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $367.316B 16.74
Pfizer (PFE) United States $249.127B 13.95
Merck (MRK) United States $221.869B 18.96
Novartis AG (NVS) Switzerland $215.800B 18.35
Eli Lilly (LLY) United States $132.844B 23.08
Novo Nordisk (NVO) Denmark $123.936B 20.05
Sanofi (SNY) France $111.008B 13.70
AstraZeneca (AZN) United Kingdom $107.876B 12.31
GlaxoSmithKline (GSK) United Kingdom $102.325B 13.44
Bristol-Myers Squibb (BMY) United States $78.630B 12.10